Novartis' Jakafi faces competition from GSK's momelotinib, while Astra looks over its shoulder at Merck in biliary tract cancer. 

AstraZeneca and Lilly put PARP1 and KRAS G12C inhibitors into their first phase 3s, while Amgen advances DLL3 into early-stage disease.

Ikena is savaged in a bear market after reporting zero remissions in a dose-escalation trial of its lead asset.

Akeso’s cadonilimab hits in its first-line study, but there’s no US data and no US partner.

Keymed’s AstraZeneca-partnered anti-Claudin18.2 ADC looks better than Astellas’s zolbetuximab – albeit on an extremely unreliable metric.

A domvanalimab triplet shows some promise in high PD-L1-expressing gastric cancer patients, but caveats abound.